{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T17:00:35Z","timestamp":1784998835993,"version":"3.55.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["A9336"],"award-info":[{"award-number":["A9336"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000771","name":"Prostate Cancer UK","doi-asserted-by":"publisher","award":["PG12-27"],"award-info":[{"award-number":["PG12-27"]}],"id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"DOI":"10.1007\/s00223-026-01558-y","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T14:48:35Z","timestamp":1784990915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Differential Effects of a First-in-Class IKK\u03b1 Inhibitor on Trabecular and Cortical Bone in a Human Prostate Cancer Xenograft Model"],"prefix":"10.1007","volume":"117","author":[{"given":"Abdullah","family":"Al-Jeffery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feier","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Sophocleous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ponzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Capulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Plevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann C. M.","family":"Fowles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon P.","family":"Mackay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Rucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4327-5306","authenticated-orcid":false,"given":"Aymen I.","family":"Idris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"1558_CR1","doi-asserted-by":"crossref","unstructured":"Hacker H, Karin M (2006) Regulation and function of IKK and IKK-related kinases. Sci.STKE. 2006:re13","DOI":"10.1126\/stke.3572006re13"},{"key":"1558_CR2","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cytogfr.2006.04.005","volume":"17","author":"G Xiao","year":"2006","unstructured":"Xiao G, Rabson AB, Young W, Qing G, Qu Z (2006) Alternative pathways of NF-kappaB activation: a double-edged sword in health and disease. Cytokine Growth Factor Rev 17:281\u2013293","journal-title":"Cytokine Growth Factor Rev"},{"key":"1558_CR3","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/35070605","volume":"410","author":"Y Hu","year":"2001","unstructured":"Hu Y, Baud V, Oga T, Kim KI, Yoshida K, Karin M (2001) IKKalpha controls formation of the epidermis independently of NF-kappaB. Nature 410:710\u2013714","journal-title":"Nature"},{"key":"1558_CR4","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1074\/jbc.M110572200","volume":"277","author":"N Sizemore","year":"2002","unstructured":"Sizemore N, Lerner N, Dombrowski N, Sakurai H, Stark GR (2002) Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B. J Biol Chem 277:3863\u20133869","journal-title":"J Biol Chem"},{"key":"1558_CR5","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nri1703","volume":"5","author":"M Karin","year":"2005","unstructured":"Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749\u2013759","journal-title":"Nat Rev Immunol"},{"key":"1558_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.molcel.2005.03.006","volume":"18","author":"KJ Park","year":"2005","unstructured":"Park KJ, Krishnan V, O\u2019Malley BW, Yamamoto Y, Gaynor RB (2005) Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation. Mol Cell 18:71\u201382","journal-title":"Mol Cell"},{"key":"1558_CR7","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1124\/jpet.105.097584","volume":"317","author":"D Wen","year":"2006","unstructured":"Wen D, Nong Y, Morgan JG, Gangurde P, Bielecki A, Dasilva J, Keaveney M, Cheng H, Fraser C, Schopf L, Hepperle M, Harriman G, Jaffee BD, Ocain TD, Xu Y (2006) A selective small molecule IkappaB Kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells. J Pharmacol Exp Ther 317:989\u20131001","journal-title":"J Pharmacol Exp Ther"},{"key":"1558_CR8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3390\/cells7100176","volume":"7","author":"A Paul","year":"2018","unstructured":"Paul A, Edwards J, Pepper C, Mackay S (2018) Inhibitory-\u03baB kinase (IKK) \u03b1 and nuclear factor-\u03baB (NF\u03baB)-inducing kinase (NIK) as anti-cancer drug targets. Cells 7:176","journal-title":"Cells"},{"key":"1558_CR9","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/cr.2008.30","volume":"18","author":"M Karin","year":"2008","unstructured":"Karin M (2008) The IkappaB kinase\u2014a bridge between inflammation and cancer. Cell Res 18:334\u2013342","journal-title":"Cell Res"},{"key":"1558_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1046\/j.1464-410X.2003.04104.x","volume":"91","author":"L Lessard","year":"2003","unstructured":"Lessard L, Mes-Masson AM, Lamarre L, Wall L, Lattouf JB, Saad F (2003) NF-kappa B nuclear localization and its prognostic significance in prostate cancer. BJU Int 91:417\u2013420","journal-title":"BJU Int"},{"key":"1558_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2174\/1389450116666150907100715","volume":"17","author":"D Verzella","year":"2016","unstructured":"Verzella D, Fischietti M, Capece D, Vecchiotti D, Del Vecchio F, Cicciarelli G, Mastroiaco V, Tessitore A, Alesse E, Zazzeroni F (2016) Targeting the NF-\u03baB pathway in prostate cancer: a promising therapeutic approach? Curr Drug Targets 17:311\u2013320","journal-title":"Curr Drug Targets"},{"key":"1558_CR12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/cells7090122","volume":"7","author":"J Staal","year":"2018","unstructured":"Staal J, Beyaert R (2018) Inflammation and NF-\u03baB signaling in prostate cancer: mechanisms and clinical implications. Cells 7:122","journal-title":"Cells"},{"key":"1558_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1242\/jcs.115.1.141","volume":"115","author":"AV Gasparian","year":"2002","unstructured":"Gasparian AV, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A, Slaga TJ, Budunova IV (2002) The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci 115:141\u2013151","journal-title":"J Cell Sci"},{"key":"1558_CR14","first-page":"4096","volume":"56","author":"JR Gingrich","year":"1996","unstructured":"Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM (1996) Metastatic prostate cancer in a transgenic mouse. Cancer Res 56:4096\u20134102","journal-title":"Cancer Res"},{"key":"1558_CR15","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/nature05656","volume":"446","author":"JL Luo","year":"2007","unstructured":"Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL, Cheresh DA, Karin M (2007) Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 446:690\u2013694","journal-title":"Nature"},{"key":"1558_CR16","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1101\/gad.220202.113","volume":"27","author":"M Ammirante","year":"2013","unstructured":"Ammirante M, Kuraishy AI, Shalapour S, Strasner A, Ramirez-Sanchez C, Zhang W, Shabaik A, Karin M (2013) An IKK\u03b1-E2F1-BMI1 cascade activated by infiltrating B cells controls prostate regeneration and tumor recurrence. Genes Dev 27:1435\u20131440","journal-title":"Genes Dev"},{"key":"1558_CR17","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/pros.24045","volume":"80","author":"M Montes","year":"2020","unstructured":"Montes M, MacKenzie L, McAllister MJ, Roseweir A, McCall P, Hatziieremia S, Underwood MA, Boyd M, Paul A, Plevin R, MacKay SP, Edwards J (2020) Determining the prognostic significance of IKKalpha in prostate cancer. Prostate 80:1188\u20131202","journal-title":"Prostate"},{"key":"1558_CR18","doi-asserted-by":"publisher","first-page":"167035","DOI":"10.1155\/2014\/167035","volume":"2014","author":"N Rucci","year":"2014","unstructured":"Rucci N, Angelucci A (2014) Prostate cancer and bone: the elective affinities. Biomed Res Int 2014:167035","journal-title":"Biomed Res Int"},{"key":"1558_CR19","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1002\/jbmr.2300","volume":"29","author":"N Wang","year":"2014","unstructured":"Wang N, Docherty FE, Brown HK, Reeves KJ, Fowles AC, Ottewell PD, Dear TN, Holen I, Croucher PI, Eaton CL (2014) Prostate cancer cells preferentially home to osteoblast-rich areas in the early stages of bone metastasis: evidence from in vivo models. J Bone Min Res 29:2688\u20132696","journal-title":"J Bone Min Res"},{"key":"1558_CR20","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3390\/cancers3010478","volume":"3","author":"MN Thobe","year":"2011","unstructured":"Thobe MN, Clark RJ, Bainer RO, Prasad SM, Rinker-Schaeffer CW (2011) From prostate to bone: key players in prostate cancer bone metastasis. Cancers (Basel) 3:478\u2013493","journal-title":"Cancers (Basel)"},{"key":"1558_CR21","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.juro.2008.04.140","volume":"180","author":"MP Roudier","year":"2008","unstructured":"Roudier MP, Morrissey C, True LD, Higano CS, Vessella RL, Ott SM (2008) Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol 180:1154\u20131160","journal-title":"J Urol"},{"key":"1558_CR22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"RE Coleman","year":"2001","unstructured":"Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165\u2013176","journal-title":"Cancer Treat Rev"},{"key":"1558_CR23","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s11914-018-0480-6","volume":"16","author":"SC Lin","year":"2018","unstructured":"Lin SC, Yu-Lee LY, Lin SH (2018) Osteoblastic factors in prostate cancer bone metastasis. Curr Osteoporos Rep 16:642\u2013647","journal-title":"Curr Osteoporos Rep"},{"key":"1558_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/path.1199","volume":"198","author":"S Kitazawa","year":"2002","unstructured":"Kitazawa S, Kitazawa R (2002) RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 198:228\u2013236","journal-title":"J Pathol"},{"key":"1558_CR25","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/pros.20678","volume":"68","author":"AP Armstrong","year":"2008","unstructured":"Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET, Dougall WC (2008) RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 68:92\u2013104","journal-title":"Prostate"},{"key":"1558_CR26","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1172\/JCI11685","volume":"107","author":"J Zhang","year":"2001","unstructured":"Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET (2001) Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107:1235\u20131244","journal-title":"J Clin Invest"},{"key":"1558_CR27","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1038\/onc.2016.436","volume":"36","author":"K Shahriari","year":"2017","unstructured":"Shahriari K, Shen F, Worrede-Mahdi A, Liu Q, Gong Y, Garcia FU, Fatatis A (2017) Cooperation among heterogeneous prostate cancer cells in the bone metastatic niche. Oncogene 36:2846\u20132856","journal-title":"Oncogene"},{"key":"1558_CR28","doi-asserted-by":"publisher","first-page":"e60983","DOI":"10.1371\/journal.pone.0060983","volume":"8","author":"R Jin","year":"2013","unstructured":"Jin R, Sterling JA, Edwards JR, DeGraff DJ, Lee C, Park SI, Matusik RJ (2013) Activation of NF-kappa B signaling promotes growth of prostate cancer cells in bone. PLoS ONE 8:e60983","journal-title":"PLoS ONE"},{"key":"1558_CR29","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/j.1464-410X.2006.06670.x","volume":"99","author":"I Vela","year":"2007","unstructured":"Vela I, Gregory L, Gardiner EM, Clements JA, Nicol DL (2007) Bone and prostate cancer cell interactions in metastatic prostate cancer. BJU Int 99:735\u2013742","journal-title":"BJU Int"},{"key":"1558_CR30","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1749-6632.2009.05315.x","volume":"1192","author":"BF Boyce","year":"2010","unstructured":"Boyce BF, Yao Z, Xing L (2010) Functions of nuclear factor kappaB in bone. Ann N Y Acad Sci 1192:367\u2013375","journal-title":"Ann N Y Acad Sci"},{"key":"1558_CR31","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/cr.2010.159","volume":"21","author":"DV Novack","year":"2011","unstructured":"Novack DV (2011) Role of NF-\u03baB in the skeleton. Cell Res 21:169\u2013182","journal-title":"Cell Res"},{"key":"1558_CR32","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1210\/edrv.20.3.0367","volume":"20","author":"T Suda","year":"1999","unstructured":"Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345\u2013357","journal-title":"Endocr Rev"},{"key":"1558_CR33","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655\u20131664","journal-title":"N Engl J Med"},{"key":"1558_CR34","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1073\/pnas.1013492108","volume":"108","author":"JY Li","year":"2011","unstructured":"Li JY, Tawfeek H, Bedi B, Yang X, Adams J, Gao KY, Zayzafoon M, Weitzmann MN, Pacifici R (2011) Ovariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand. Proc Natl Acad Sci U S A 108:768\u2013773","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1558_CR35","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1101\/gad.13.8.1015","volume":"13","author":"MA Lomaga","year":"1999","unstructured":"Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A, Morony S, Capparelli C, Van G, Kaufman S, van der Itie HA, Wakeham A, Khoo A, Sasaki W, Cao T, Penninger Z, Paige JM, Lacey CJ, Dunstan DL, Boyle CR, Goeddel WJ, Mak DV TW (1999) TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 13:1015\u20131024","journal-title":"Genes Dev"},{"key":"1558_CR36","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/jbmr.4","volume":"25","author":"JE Otero","year":"2010","unstructured":"Otero JE, Dai S, Alhawagri MA, Darwech I, Abu-Amer Y (2010) IKKbeta activation is sufficient for RANK-independent osteoclast differentiation and osteolysis. J Bone Min Res 25:1282\u20131294","journal-title":"J Bone Min Res"},{"key":"1558_CR37","doi-asserted-by":"publisher","first-page":"54841","DOI":"10.1074\/jbc.M406392200","volume":"279","author":"ML Chaisson","year":"2004","unstructured":"Chaisson ML, Branstetter DG, Derry JM, Armstrong AP, Tometsko ME, Takeda K, Akira S, Dougall WC (2004) Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha. J Biol Chem 279:54841\u201354848","journal-title":"J Biol Chem"},{"key":"1558_CR38","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1073\/pnas.0708576105","volume":"105","author":"S Vaira","year":"2008","unstructured":"Vaira S, Johnson T, Hirbe AC, Alhawagri M, Anwisye I, Sammut B, O\u2019Neal J, Zou W, Weilbaecher KN, Faccio R, Novack DV (2008) RelB is the NF-kappaB subunit downstream of NIK responsible for osteoclast differentiation. Proc Natl Acad Sci U S A 105:3897\u20133902","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1558_CR39","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.bcp.2014.10.017","volume":"92","author":"L Verstrepen","year":"2014","unstructured":"Verstrepen L, Beyaert R (2014) Receptor proximal kinases in NF-kappaB signaling as potential therapeutic targets in cancer and inflammation. Biochem Pharmacol 92:519\u2013529","journal-title":"Biochem Pharmacol"},{"key":"1558_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1423-0127-20-3","volume":"20","author":"WC Huang","year":"2013","unstructured":"Huang WC, Hung MC (2013) Beyond NF-kappaB activation: nuclear functions of IkappaB kinase alpha. J Biomed Sci 20:3","journal-title":"J Biomed Sci"},{"key":"1558_CR41","doi-asserted-by":"publisher","first-page":"7043","DOI":"10.1021\/acs.jmedchem.7b00484","volume":"60","author":"NG Anthony","year":"2017","unstructured":"Anthony NG, Baiget J, Berretta G, Boyd M, Breen D, Edwards J, Gamble C, Gray AI, Harvey AL, Hatziieremia S, Ho KH, Huggan JK, Lang S, Llona-Minguez S, Luo JL, McIntosh K, Paul A, Plevin RJ, Robertson MN, Scott R, Suckling CJ, Sutcliffe OB, Young LC, Mackay SP (2017) Inhibitory kappa B kinase \u03b1 (IKK\u03b1) inhibitors that recapitulate their selectivity in cells against isoform-related biomarkers. J Med Chem 60:7043\u20137066","journal-title":"J Med Chem"},{"key":"1558_CR42","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.3390\/molecules29153515","volume":"29","author":"C Riley","year":"2024","unstructured":"Riley C, Ammar U, Alsfouk A, Anthony NG, Baiget J, Berretta G, Breen D, Huggan J, Lawson C, McIntosh K, Plevin R, Suckling CJ, Young LC, Paul A, Mackay SP (2024) Design and synthesis of novel aminoindazole-pyrrolo[2,3-b]pyridine inhibitors of IKK\u03b1 that selectively perturb cellular non-canonical NF-\u03baB signalling. Molecules 29:3515","journal-title":"Molecules"},{"key":"1558_CR43","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/978-1-4939-8997-3_5","volume":"1914","author":"S Marino","year":"2019","unstructured":"Marino S, Bishop RT, de Ridder D, Delgado-Calle J, Reagan MR (2019) 2D and 3D in vitro co-culture for cancer and bone cell interaction studies. Methods Mol Biol 1914:71\u201398","journal-title":"Methods Mol Biol"},{"key":"1558_CR44","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/978-1-4939-8997-3_7","volume":"1914","author":"S Marino","year":"2019","unstructured":"Marino S, Idris AI (2019) Analysis of signaling pathways by western blotting and immunoprecipitation. Methods Mol Biol 1914:131\u2013143","journal-title":"Methods Mol Biol"},{"key":"1558_CR45","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-1-4939-8997-3_2","volume":"1914","author":"IP Perpetuo","year":"2019","unstructured":"Perpetuo IP, Bourne LE, Orriss IR (2019) Isolation and generation of osteoblasts. Methods Mol Biol 1914:21\u201338","journal-title":"Methods Mol Biol"},{"key":"1558_CR46","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-8997-3_1","volume":"1914","author":"N Rucci","year":"2019","unstructured":"Rucci N, Zallone A, Teti A (2019) Isolation and generation of osteoclasts. Methods Mol Biol 1914:3\u201319","journal-title":"Methods Mol Biol"},{"key":"1558_CR47","first-page":"4545","volume":"24","author":"AI Idris","year":"2010","unstructured":"Idris AI, Krishnan M, Simic P, Landao-Bassonga E, Mollat P, Vukicevic S, Ralston SH (2010) Small molecule inhibitors of IkappaB kinase signaling inhibit osteoclast formation in vitro and prevent ovariectomy-induced bone loss in vivo. FASEB J Off Public Fed Am Soc Exp Biol 24:4545\u20134555","journal-title":"FASEB J Off Public Fed Am Soc Exp Biol"},{"key":"1558_CR48","first-page":"23","volume":"294","author":"LG Rodriguez","year":"2005","unstructured":"Rodriguez LG, Wu X, Guan JL (2005) Wound-healing assay. Methods Mol Biol 294:23\u201329","journal-title":"Methods Mol Biol"},{"key":"1558_CR49","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/978-1-4939-8997-3_28","volume":"1914","author":"RJ van \u2018t Hof","year":"2019","unstructured":"van \u2018t Hof RJ, Dall\u2019Ara E (2019) Analysis of bone architecture in rodents using micro-computed tomography. Methods Mol Biol 1914:507\u2013531","journal-title":"Methods Mol Biol"},{"key":"1558_CR50","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/978-1-4939-8997-3_24","volume":"1914","author":"RG Erben","year":"2019","unstructured":"Erben RG, Glosmann M (2019) Histomorphometry in rodents. Methods Mol Biol 1914:411\u2013435","journal-title":"Methods Mol Biol"},{"key":"1558_CR51","first-page":"297","volume":"18","author":"OH Sanchez-Sweatman","year":"1998","unstructured":"Sanchez-Sweatman OH, Orr FW, Singh G (1998) Human metastatic prostate PC3 cell lines degrade bone using matrix metalloproteinases. Invasion Metastasis 18:297\u2013305","journal-title":"Invasion Metastasis"},{"key":"1558_CR52","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/bcr2781","volume":"12","author":"YC Chen","year":"2010","unstructured":"Chen YC, Sosnoski DM, Mastro AM (2010) Breast cancer metastasis to the bone: mechanisms of bone loss. Breast Cancer Res 12:215","journal-title":"Breast Cancer Res"},{"key":"1558_CR53","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.eururo.2012.02.054","volume":"61","author":"MM Center","year":"2012","unstructured":"Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F (2012) International variation in prostate cancer incidence and mortality rates. Eur Urol 61:1079\u20131092","journal-title":"Eur Urol"},{"key":"1558_CR54","first-page":"71","volume":"58","author":"A Jemal","year":"2008","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71\u201396","journal-title":"CA Cancer J Clin"},{"key":"1558_CR55","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1053\/hp.2000.6698","volume":"31","author":"L Bubendorf","year":"2000","unstructured":"Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31:578\u2013583","journal-title":"Hum Pathol"},{"key":"1558_CR56","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s00223-018-0406-4","volume":"103","author":"S Marino","year":"2018","unstructured":"Marino S, Bishop RT, Mollat P, Idris AI (2018) Pharmacological inhibition of the skeletal IKKbeta reduces breast cancer-induced osteolysis. Calcif Tissue Int 103:206\u2013216","journal-title":"Calcif Tissue Int"},{"key":"1558_CR57","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.canlet.2019.02.032","volume":"450","author":"RT Bishop","year":"2019","unstructured":"Bishop RT, Marino S, de Ridder D, Allen RJ, Lefley DV, Sims AH, Wang N, Ottewell PD, Idris AI (2019) Pharmacological inhibition of the IKKepsilon\/TBK-1 axis potentiates the anti-tumour and anti-metastatic effects of Docetaxel in mouse models of breast cancer. Cancer Lett 450:76\u201387","journal-title":"Cancer Lett"},{"key":"1558_CR58","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.canlet.2017.09.034","volume":"410","author":"S Marino","year":"2017","unstructured":"Marino S, Bishop RT, Logan JG, Mollat P, Idris AI (2017) Pharmacological evidence for the bone-autonomous contribution of the NFkappaB\/beta-catenin axis to breast cancer related osteolysis. Cancer Lett 410:180\u2013190","journal-title":"Cancer Lett"},{"key":"1558_CR59","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s00223-018-0406-4","volume":"103","author":"S Marino","year":"2018","unstructured":"Marino S, Bishop RT, Mollat P, Idris AI (2018) Pharmacological inhibition of the skeletal IKKbeta reduces breast cancer-induced osteolysis. Calcif Tissue Int 103:206","journal-title":"Calcif Tissue Int"},{"key":"1558_CR60","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s00223-019-00538-9","volume":"105","author":"S Marino","year":"2019","unstructured":"Marino S, Bishop RT, Carrasco G, Logan JG, Li B, Idris AI (2019) Pharmacological inhibition of NFkappaB reduces prostate cancer related osteoclastogenesis in vitro and osteolysis ex vivo. Calcif Tissue Int 105:204","journal-title":"Calcif Tissue Int"},{"key":"1558_CR61","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2164\/jandrol.111.013987","volume":"33","author":"PJ Hensley","year":"2012","unstructured":"Hensley PJ, Kyprianou N (2012) Modeling prostate cancer in mice: limitations and opportunities. J Androl 33:133\u2013144","journal-title":"J Androl"},{"key":"1558_CR62","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10616-014-9694-3","volume":"67","author":"T Goto","year":"2015","unstructured":"Goto T, Hagiwara K, Shirai N, Yoshida K, Hagiwara H (2015) Apigenin inhibits osteoblastogenesis and osteoclastogenesis and prevents bone loss in ovariectomized mice. Cytotechnology 67:357\u2013365","journal-title":"Cytotechnology"},{"key":"1558_CR63","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.neo.2017.08.007","volume":"19","author":"AE Paiva","year":"2017","unstructured":"Paiva AE, Lousado L, Almeida VM, Andreotti JP, Santos GSP, Azevedo PO, Sena IFG, Prazeres P, Borges IT, Azevedo V, Mintz A, Birbrair A (2017) Endothelial cells as precursors for osteoblasts in the metastatic prostate cancer bone. Neoplasia 19:928\u2013931","journal-title":"Neoplasia"},{"key":"1558_CR64","doi-asserted-by":"publisher","first-page":"5194","DOI":"10.1158\/0008-5472.CAN-10-4374","volume":"71","author":"YC Lee","year":"2011","unstructured":"Lee YC, Cheng CJ, Bilen MA, Lu JF, Satcher RL, Yu-Lee LY, Gallick GE, Maity SN, Lin SH (2011) BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res 71:5194\u20135203","journal-title":"Cancer Res"},{"key":"1558_CR65","first-page":"2697","volume":"118","author":"ZG Li","year":"2008","unstructured":"Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin SH, Maity S, Navone NM (2008) Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest 118:2697\u20132710","journal-title":"J Clin Invest"},{"key":"1558_CR66","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/jbmr.2108","volume":"29","author":"Z Yao","year":"2014","unstructured":"Yao Z, Li Y, Yin X, Dong Y, Xing L, Boyce BF (2014) NF-kappaB RelB negatively regulates osteoblast differentiation and bone formation. J Bone Min Res 29:866\u2013877","journal-title":"J Bone Min Res"},{"key":"1558_CR67","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.1074\/jbc.M112.426080","volume":"288","author":"Y Furuya","year":"2013","unstructured":"Furuya Y, Inagaki A, Khan M, Mori K, Penninger JM, Nakamura M, Udagawa N, Aoki K, Ohya K, Uchida K, Yasuda H (2013) Stimulation of bone formation in cortical bone of mice treated with a receptor activator of nuclear factor-kappaB ligand (RANKL)-binding peptide that possesses osteoclastogenesis inhibitory activity. J Biol Chem 288:5562\u20135571","journal-title":"J Biol Chem"},{"key":"1558_CR68","doi-asserted-by":"publisher","first-page":"e0138710","DOI":"10.1371\/journal.pone.0138710","volume":"10","author":"S Shukla","year":"2015","unstructured":"Shukla S, Shankar E, Fu P, MacLennan GT, Gupta S (2015) Suppression of NF-kappaB and NF-kappaB-regulated gene expression by apigenin through IkappaBalpha and IKK pathway in TRAMP mice. PLoS ONE 10:e0138710","journal-title":"PLoS ONE"},{"key":"1558_CR69","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/cr.2008.273","volume":"18","author":"JF Clement","year":"2008","unstructured":"Clement JF, Meloche S, Servant MJ (2008) The IKK-related kinases: from innate immunity to oncogenesis. Cell Res 18:889\u2013899","journal-title":"Cell Res"},{"key":"1558_CR70","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/ni.2065","volume":"12","author":"A Oeckinghaus","year":"2011","unstructured":"Oeckinghaus A, Hayden MS, Ghosh S (2011) Crosstalk in NF-kappaB signaling pathways. Nat Immunol 12:695\u2013708","journal-title":"Nat Immunol"},{"key":"1558_CR71","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/nature01576","volume":"423","author":"Y Yamamoto","year":"2003","unstructured":"Yamamoto Y, Verma UN, Prajapati S, Kwak YT, Gaynor RB (2003) Histone H3 phosphorylation by IKK-alpha is critical for cytokine-induced gene expression. Nature 423:655\u2013659","journal-title":"Nature"},{"key":"1558_CR72","doi-asserted-by":"publisher","first-page":"6717","DOI":"10.1038\/sj.onc.1209937","volume":"25","author":"ND Perkins","year":"2006","unstructured":"Perkins ND (2006) Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene 25:6717\u20136730","journal-title":"Oncogene"},{"key":"1558_CR73","doi-asserted-by":"crossref","unstructured":"Cunningham D, You Z (2015) In vitro and in vivo model systems used in prostate cancer research. J Biol Methods 2","DOI":"10.14440\/jbm.2015.63"},{"key":"1558_CR74","unstructured":"UK CR (ed) (2018)"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-026-01558-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-026-01558-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-026-01558-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T16:01:37Z","timestamp":1784995297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-026-01558-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1558"],"URL":"https:\/\/doi.org\/10.1007\/s00223-026-01558-y","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.I. Idris is a founder and shareholder of ArthElix Ltd. (UK, registration No: SC288265), a company established to develop novel TRAF\/ NF\u03baB inhibitors as anti-rheumatic and anti-metastatic drugs. Simon P. Mackay is an inventor on a patent concerning the use of the first-in-class IKK\n                      \u03b1\n                      inhibitors described for the treatment of cancer. Other authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"122"}}